about
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeTreatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection.Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma.Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1.Tumor spread through air space (STAS) is an important predictor of clinical outcome in stage IA lung adenocarcinoma.Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.Understanding and targeting resistance mechanisms in NSCLC.Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas.APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling.Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.The Role of Chromosomal Instability in Cancer and Therapeutic Responses.Time for change: a new training programme for morpho-molecular pathologists?Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.Early Detection and Chemoprevention of Lung Cancer.Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Defining the molecular pathology of pancreatic body and tail adenocarcinoma.Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers.Determinants and clinical implications of chromosomal instability in cancer.
P2860
Q33913152-B04AE029-A00E-4AC2-93C4-F3EB868A97EBQ38631019-B332C432-B248-4148-821F-7742D48F6FCDQ38661911-9EEAC35F-975E-4F73-80D6-10F1B075C3B8Q38669769-A62D40A7-B48B-41EE-B78F-B7CFB4790867Q38683041-5B356F58-603A-4EEC-9A3D-CF4407B1BD68Q39457284-C13FBDCC-8111-47AA-98DE-84D75E33DBE0Q40496979-2D33FC2C-601A-4536-9795-1C8547458596Q41615232-B7D0AE34-1A89-4888-BB17-107D1996900EQ42026653-AFEA5849-8CBE-4521-8684-DB772EDF2A5AQ42357315-814FD0A8-330A-4FCC-A18F-25824A3E2654Q42641203-73997389-F02A-4F70-B112-CA3F2EF2547CQ45886897-CE531F62-1812-489B-9234-760A855C1C5AQ45983599-0560C975-5D9B-484E-A787-DED812E6030AQ46589487-F28DE868-329F-4D24-A339-A76C0A41068EQ46915997-F492EEC2-CEEA-4967-9109-EBE7791BF116Q47111129-158BEBF9-B929-460C-BD1A-FFB5E0D05A1DQ47133741-C512C24E-6742-4465-9463-5F70196DF5DAQ47134647-ABD0F84E-5AAD-493B-A569-F26E13E96A6DQ47150991-57C25E10-E801-4FB1-9DEF-839C2AA3060EQ47159366-8DE792E0-13BB-405C-B6B2-E4F4D995D51DQ47163492-1F915425-D1D4-4671-8B4F-85577A4786A1Q47555165-7F71DD09-9883-4D7E-96C8-D05FB5BE2E74Q47558605-32586CC2-F8EB-47B8-96AA-4552AC8CA1BCQ47568875-03DA73D3-E93C-49C8-BF6D-439BB68198D0Q47569690-1EFE0154-D05A-490A-8EAE-1DA48BBC76CBQ47570870-E879D187-73D1-4424-944E-14BDE2939844Q47637197-6A44EFA1-24F7-4770-AE46-41EE08710B8DQ47682423-91E0DCF3-2E8E-4906-8029-BFC54538140CQ47708395-F7911321-E450-42DD-B4BD-023005D4E668Q47735303-F2DEC272-D380-4976-B637-A58FE6F8B359Q47843948-15682FE7-6C88-4AB8-A500-4CB80EB63B0DQ47936526-59E38CE5-2F56-4493-8F78-2E0544BD9970Q48178985-F68C3FE4-6BD6-4906-8012-D06E3AF2D85AQ48229462-A5063805-9FB2-45C4-A937-90FD135A9138Q48240221-B3DC7E58-1DA5-4B15-91E8-9AFD6C1C3293Q48282479-31A7C631-C268-49A8-9402-30CC498410F7Q48335581-09483E0E-FF5C-4DCE-AFD2-02089EE439A0Q48501675-0955AA54-6F0D-4E2B-A35E-53311EBE0ED5Q48510203-3073152A-111D-4043-86E2-560A923C3234Q49347721-7FAAF022-DBC2-49EB-87FC-27D844129166
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Tracking the Evolution of Non-Small-Cell Lung Cancer.
@en
type
label
Tracking the Evolution of Non-Small-Cell Lung Cancer.
@en
prefLabel
Tracking the Evolution of Non-Small-Cell Lung Cancer.
@en
P2093
P50
P356
P1476
Tracking the Evolution of Non-Small-Cell Lung Cancer.
@en
P2093
Allan Hackshaw
Andrew Rowan
Anne M Quinn
Apostolos Nakas
Asia Ahmed
Babikir Ismail
Babu Naidu
Brendan O'Sullivan
Christopher Abbosh
David A Moore
P304
P356
10.1056/NEJMOA1616288
P407
P50
P577
2017-04-26T00:00:00Z